Choices of therapeutic strategies for hepatocellular carcinoma (HCC)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00025099

Enrollment

200

Registered

2021-04-22

Start date

2021-11-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C22.0

Interventions

Group 1: A survey on the choices of therapeutic strategies for HCC is planned to define the degree of agreement in the selection of therapeutic strategies depending on the treating specialist discipli

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All specialists at surgical, internal medicine and radiation therapy departments involved in the treatment of liver cancer patients are eligible to take part in the survey.

Exclusion criteria

Exclusion criteria: Participants did not completely answer the survey.

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the therapy recommendation for the treatment of hepatocellular carcinoma given by the survey participants. This is collected as part of an online questionnaire as soon as the participants have completely answered the survey.	—

Countries

Germany

Contacts

Public ContactNuh Rahbari

Chirurgische Klinik Universitätsmedizin Mannheim

nuh.rahbari@umm.de+49-(0)621 383 3591

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026